Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-11-15
2005-11-15
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S258100, C514S262100, C514S269000, C514S463000, C514S464000
Reexamination Certificate
active
06964968
ABSTRACT:
Viral infections selected from the group consisting of herpes simplex virus, varicella zoster virus, respiratory syncytial virus and cytomegalovirus can be treated by administering to the host a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof;wherein Y, Ra, and R1 are as defined herein. The compounds and salts can also be used to inhibit viral replication of these viruses in cells.
REFERENCES:
patent: 5041449 (1991-08-01), Belleau et al.
patent: 5565438 (1996-10-01), Chu et al.
patent: 5792733 (1998-08-01), Chu et al.
patent: 5792772 (1998-08-01), Bianco et al.
patent: 5817667 (1998-10-01), Chu et al.
patent: 5922867 (1999-07-01), Mansour et al.
patent: 5955610 (1999-09-01), Nguyen-Ba et al.
patent: 6022876 (2000-02-01), Chu et al.
patent: 6069250 (2000-05-01), Mansour et al.
patent: 6069252 (2000-05-01), Liotta et al.
patent: 6274589 (2001-08-01), Chu et al.
patent: WO 92/18517 (1992-10-01), None
patent: WO 92/20669 (1992-11-01), None
patent: WO 95/07086 (1995-03-01), None
patent: WO 96/07413 (1996-03-01), None
patent: WO 97/31706 (1997-06-01), None
patent: WO 98/20879 (1998-05-01), None
patent: WO 00/47759 (2000-08-01), None
patent: WO 00/57861 (2000-10-01), None
patent: WO 01/06986 (2001-02-01), None
Nicholas A. Meanwell and Mark Krystal, “Respiratory syncytial virus: recent progress towards the discovery of effective prophylactic and therapeutic agents,” Therapeutic focus (reviews), DDT vol. 5, No. Jun. 6, 2000, pp. 241-252.
Jean Bédard et al. “A Comparative Study of the Anti-Human Cytomegalovirus Activities and Toxicities of a Tetrahydrofuran Phosphonate Analogue of Guanosine and Cidofovir” Antimicrobial Agents and Chemotherapy, Mar. 1999, p. 557-567, vol. 43, No. 3.
Arthur F. Lewis et al. “Alnhibition of Human Cytomegalovirus in Culture by Alkenyl Guanine Analogus of the Thiazolo [4,5-d] Pyrimidine Ring System,” Antimicrobial Agents and Chemotherapy, Dec. 1994, p. 2889-2895, vol. 38, No. 12.
Eng-Chun Mar et al. “Some nucleoside analogs with anti-human immunodeficiency virus activity inhibit replication of Epstein-Bar virusus,” Antiviral Research 28, (1995) 1-11.
Kryzysztof Bednarski et al. “AInhibitory activities of Herpes Simplex Viruses Type 1 and 2 and Human Cytomegalovirus By Stereoisomers of 2'-Deoxy-3'-Oxa-5(E)-(2-Bromovinyl) Uridines and Their 4'-Thio Analogues,” Bioorganic & Medicinal Chemistry Letters, vol. 4, No. 22 pp. 2667-2672, 1994.
Kai-Ming Chou, Marina Kukhanova, and Yung-Chi Cheng “AA Noval Action of Human Apurinic/Apyrimidinic Endonuclease,” J. Biol. Chem., vol. 275, Issue 40, 31009-31015, Oct. 6, 2000.
Steve Weitman et al. “A The New Dioxolane, (-)-2'-oxacytidine (BCH-4556, Troxacitabine), Has Activity Against Panceratic Human Tumor Xenografts,” Clinical Cancer Research vol. 6, 1574-1578, Apr. 2000.
Shafaat A. Rabbani et al., “Effect of Nucleoside Analogue BCH-4556 on Prostate Cancer Growth and MetastasesIn Vitro and in Vivo,” Cancer Research 58, pp. 3461-3465, Aug. 1, 1998.
P.M. Schwartz et al. “μ-L-1,3-Dioxolane-Cytidine: A Novel Nucleoside That Inhibits Proliferation and Induces Differation of Keratinocytes in vitro,” Skin Pharmacol. Appl Skin Physiol 1998, 11:207-213.
K.L. Grove et al., “Beta-L-(-)-Diocolane cytidine (μ-L-(-)-OddC) As A Potent Compound For The Treatment of Cancer,” Nucleosides & Nucleotides, 16(7-9), 1220-1233 (1997).
Salam A. Kadhim et al. “Potent Antitumor Activity of a Novel Nucleoside Analogue, BCH-4556 (μ-L-Dioxolane-cytidine), in Human Renal Cell Carcinoma Xenograft Tumor Models,” Cancer Research 57, 4803-4810, Nov. 1, 1997.
Kristie L. Grove and Yung-Chi Cheng, “Uptake and Metabolism of the New Anticancer Compound μ-L-(-)-Dioxolane-Cytidine In Human Prostate Carcinoma DU-145 Cells,” Cancer Research 56, 4187-5191, Sep. 15, 1996.
Migyoung Lee et al. “Dioxolane Cytosine Nucleosides as Anti-hepatitis B Agents,” Bioorganic & Medicinal Chemistry Letters, vol. 5, No. 17, pp. 2011-2014, 1995.
Kristie L. Grove et al., “Anticancer Activity of μ-L-Dioxolane-cytidine, a Novel Nucleoside Analogue with the Unnatural L. Configuration,” Cancer Research 55, 3008-3011, Jul. 15, 1995.
Tarek S. Mansour et al. “Structure-Activity Relationships Among a New Class of Antiviral Heterosubstituted 2',3'-Dideoxynucleoside Analogues,” Nucleosides & Nucleotides, 14(3-5), 627-635 (1995).
L.L. Siu et al. “Activity of (-)-2'-deoxy-3'oxacytidine (BCH-4556)against human tumor colony-forming units,” Annals of Oncology 9:885-891, 1998.
Laura E. Moore, et al., “Preclinical pharmacmacokinetics of μ-L-dioxolane-cytidine, a novel anticancer agent, in rats,” Cancer Chemother Pharmacol (1997) 39:532-536.
Mei-Zhen Luo et al., “Synthesis and BiologicalEvaluation of L-and-D-Configuration 1,3-Dioxolane 5-Azacytosine and 6-Azathymine Nucleosides,”Bioorganic & MedicinalChemistry Letters 10 (2000), 2145-2148.
M. Arshad Siddiqui et al., “Synthesis of Optically Pure dioxolane Nucleosides and Their Anti-HIV Activity,” Abstracts of papers of the National Meeting of the American Chemical Society, vol. 205, 1993, pp. P01 XP000910349 Abstract.
Zhengxian Gu et al., “Mechanism of Action and In Vitro Activity of 1',3'-Dioxolanylpurine Nucleoside Analogues Against Sensitive and Drug-Resistant Human Immunodeficiency Virus Type 1 Variants,” Antimicrobial Agents and Chemotherapy, Oct. 1999, pp. 2376-2382, vol. 43, No. 10.
International Search Report, International Applicaition No. PCT/CA 00/01094, Apr. 18, 2001.
Bedard Jean
Giles Francis J.
Rando Robert F.
McIntosh III Traviss C.
Millen White Zelano & Branigan P.C.
Shire Biochem Inc.
Wilson James O.
LandOfFree
Method for the treatment or prevention of viral infection... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the treatment or prevention of viral infection..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the treatment or prevention of viral infection... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3519759